Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group
Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group
复制标题
DOI：
10.1111/j.1365-2559.2011.04096.x
复制
发表时间：
2012-01-01
期刊：
影响因子：
6.4
通讯作者：
Aozasa, Katsuyuki
中科院分区：
文献类型：
--
作者：
Wada, Naoki;Zaki, Mona A. A.;Aozasa, Katsuyuki
目的：评估M1和M2型肿瘤相关巨噬细胞（TAM）在弥漫性大B细胞淋巴瘤（DLBCL）行为中的作用。方法和结果：对101例DLBCL进行HLA-DR/CD68（M1）或CD163/CD68（M2）双重免疫组化染色。 CD68+细胞代表TAM的总数。计算双阳性细胞的平均数，并将截止值设定为平均计数数，即。 e. M1 TAM 和 M2 TAM 分别为 30.7 和 27.0。总 TAM 的值设置为总计数的第 90 个百分位数，即。 e. 132.3。病例分为三对：高（34例）和低（67例）M1 TAM组、高（39例）和低（62例）M2 TAM组以及高（10例）和低（91例）总TAM组。高M2 TAM组和低M2 TAM组之间以及高总TAM组和低总TAM组之间总生存率差异有统计学意义（P < 0.01）。多变量分析显示，肿块体积大和M2 TAM数量较多是预后不良的重要因素（P < 0.05）。结论：对于DLBCL患者的预后，对特定类型巨噬细胞（M1和M2类型）的估计优于对TAM整体（CD68+细胞）的估计。
Aims: To evaluate the role of tumour-associated macrophages (TAMs) of the M1 and M2 types in the behaviour of diffuse large B-cell lymphoma (DLBCL).Methods and results: Double immunohistochemical staining of HLA-DR/CD68 (M1) or CD163/CD68 (M2) was performed in 101 cases of DLBCL. CD68+ cells represent the total number of TAMs. The average number of double-positive cells was counted, and the cut-off value was set at the mean number of counts, i. e. 30.7 and 27.0 for M1 TAMs and M2 TAMs, respectively. That for total TAMs was set at the 90th percentile number of total counts, i. e. 132.3. Cases were categorized into three pairs: high (34 cases) and low (67 cases) M1 TAM groups, high (39 cases) and low (62 cases) M2 TAM groups, and high (10 cases) and low (91 cases) total TAM groups. The difference in overall survival rates was statistically significant between the high and low M2 TAM groups (P < 0.01) and between the high and low total TAM groups (P < 0.05). Multivariate analysis revealed that the presence of a bulky mass and a higher number of M2 TAMs were significant factors for poor prognosis (P < 0.05).Conclusions: Estimation of specific type of macrophages, of the M1 and M2 types, is superior to the estimation of TAMs as a whole (CD68+ cells) for prediction of the prognosis of DLBCL patients.